Implantable Drug Delivery Devices Market To Experience Steady Growth, Projected To Reach ...
The Global Implantable Drug Delivery Devices Market was valued at USD 26.7 Bn in 2023. It is expected to reach USD 57.1 Bn by 2033, with a CAGR of 8.1% ...
Long Island Press3 天
Heart health: Treating Afib can prevent strokes, cardiac deaths
If left untreated, Afib can lead to stroke, heart failure and premature cardiac death. But fortunately, Afib is treatable and, in some cases, preventable.
KORU Medical Systems Has A Long Runway
The SCIg market is growing rapidly, with KORU Medical Systems outperforming competitors by capturing market share. Read why I ...
Living with pain: Woman copes with RSD
Bonnie Scherer of Prior Lake is no stranger to pain. She experiences pain equal to or exceeding that of childbirth on a daily basis.  The pain ...
GP issues urgent warning to anyone using three common prescription medicines
Dr Asif Ahmed has taken to TikTok to alert patients to the long term side effects - including addiction - of using three ...
GMA14 天
FDA approves new type of non-opioid pain medication, 1st of its kind in more than 20 years
The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain. The drug, called Journavx (suzetrigine) ...
BGR14 天
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
If you buy through a BGR link, we may earn an affiliate commission, helping support our expert product labs. For the first time in over two decades, the U.S. Food and Drug Administration (FDA) has ...
btimesonline14 天
FDA Greenlights Groundbreaking Pain Medication, But Is It Effective Enough?
The U.S. Food and Drug Administration (FDA) has approved Journavx, the first new class of pain medication in more than two decades. Developed by Vertex Pharmaceuticals, the drug-known generically as ...
U.S. News & World Report14 天
What to Know About Journavx, the Non-Opioid Pain Medication Just Approved by the FDA
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years. “Today’s approval is an important public health ...
pix1114 天
New type of non-opioid pain medication approved by FDA
(The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.
Yahoo14 天
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA's sign-off on the medication comes as the agency says it is prioritizing supporting the development of non-opioid pain treatment. Suzetrigine is the first non-opioid analgesic – or ...
WPXI14 天
FDA approves new medication as alternative to opioids for pain treatment
The Food and Drug Administration has approved a new pain medication that could take the place of opioids for those experiencing moderate to severe acute pain. The drug is Journavx, or the generic ...